Invasive Ductal Carcinoma of the Breast in a Transgender Man: A Case Report

There is limited literature about breast cancer in the transgender population. Very little is known about how gender-affirming hormone therapy affects their breast cancer risk. On the other end, for those diagnosed with breast cancer, there are no clinical guidelines to manage their breast cancer, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Heng, Yujing J., Zhang, Kevin J., Valero, Monica G., Baker, Gabrielle M., Fein-Zachary, Valerie J., Irwig, Michael S., Wulf, Gerburg M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601725/
https://www.ncbi.nlm.nih.gov/pubmed/37900827
http://dx.doi.org/10.1159/000529859
Descripción
Sumario:There is limited literature about breast cancer in the transgender population. Very little is known about how gender-affirming hormone therapy affects their breast cancer risk. On the other end, for those diagnosed with breast cancer, there are no clinical guidelines to manage their breast cancer, specifically, how to manage their gender-affirming hormone therapy during breast cancer treatment. Here, we report a 52-year-old transman diagnosed with a grade 2 invasive ductal carcinoma (ER+/PR+/HER2−), and ductal carcinoma in situ (DCIS) of intermediate grade. We discussed his risk factors as well as treatment options.

Ejemplares similares